Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ORIC
Stock Latest News
Ratings
Promising Outlook for Oric Pharmaceuticals: Buy Rating Backed by Prostate Cancer Program Developments and Strong Financial Position
6d ago
ORIC
Premium
Ratings
ORIC Pharmaceuticals: Promising Oncology Developments and Strategic Trials Support Buy Rating
9d ago
ORIC
Premium
The Fly
Oric Pharmaceuticals management to meet virtually with Cantor Fitzgerald
1M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals management to meet virtually with Cantor Fitzgerald
1M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals assumed with a Buy at Guggenheim
2M ago
ORIC
Premium
Ratings
Oric Pharmaceuticals’ ORIC-944: A Promising PRC2 Inhibitor with Strategic Partnerships and Market Potential
2M ago
ORIC
Premium
Company Announcements
ORIC Pharmaceuticals Reports Q2 2025 Financial Results
2M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals appoints Kevin Brodbeck CTO
2M ago
ORIC
Premium
Ratings
Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating
2M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals price target lowered to $19 from $22 at H.C. Wainwright
2M ago
ORIC
Premium
Company Announcements
Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials
2M ago
ORIC
Premium
Company Announcements
Oric Pharmaceuticals Focuses on Lead Clinical Programs
2M ago
8K
ORIC
Premium
The Fly
Oric Pharmaceuticals reports Q2 EPS (47c), consensus (44c)
2M ago
ORIC
Premium
The Fly
Oric Pharmaceuticals initiated with a Buy at Ladenburg
4M ago
ORIC
Premium
Company Announcements
Oric Pharmaceuticals Elects Directors at Annual Meeting
4M ago
8K
ORIC
Premium
The Fly
JPMorgan biotech/pharma analysts hold analyst/industry conference call
5M ago
JNJ
PFE
Premium
The Fly
Oric Pharmaceuticals files to sell 19.23M shares of common stock for holders
5M ago
ORIC
Premium
Ratings
Promising Potential of ORIC-944 in mCRPC Treatment Drives Buy Rating and $22 Price Target
5M ago
ORIC
Premium
The Fly
Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz
5M ago
S
AI
Premium
The Fly
Oric Pharmaceuticals data ‘home run scenario,’ says JPMorgan
5M ago
ORIC
Premium
Ratings
Buy Rating for Oric Pharmaceuticals Driven by Promising ORIC-944 Study Results and Undervaluation
5M ago
ORIC
Premium
The Fly
Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis
5M ago
A
S
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
